This content is restricted to members.
To view our premium content, sign up for a membership:
This content is restricted to members.
To view our premium content, sign up for a membership:
1. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15(4):477–88.
2. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016 Oct 1;37(5):467–520.
3. Balen A. The pathophysiology of polycystic ovary syndrome: Trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol. 2004;18(5 SPEC. ISS.):685–706.
4. Azziz R. Polycystic Ovary Syndrome. Obstetrics & Gynecology. 2018 Aug;132(2):321–36.
5. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction. 2016 Dec;31(12):2841–55.
6. Unfer V, Dinicola S, Russo M. A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes? Int J Mol Sci. 2023 Mar 25;24(7):6213.
7. Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–58.
8. Unfer V, Porcaro G. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2014;7(5):623–31.
9. Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. Int J Endocrinol. 2016:2016:3204083.
10. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al. Divergences in Insulin Resistance Between the Different Phenotypes of the Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2013 Apr 1;98(4):E628–37.